TRAP1 regulates the response of colorectal cancer cells to hypoxia and inhibits ribosome biogenesis under conditions of oxygen deprivation.
TNF receptor‑associated protein 1
glycolysis
hypoxia
hypoxia inducible factor 1α
ribosome biosynthesis
Journal
International journal of oncology
ISSN: 1791-2423
Titre abrégé: Int J Oncol
Pays: Greece
ID NLM: 9306042
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
11
02
2022
accepted:
12
04
2022
entrez:
11
5
2022
pubmed:
12
5
2022
medline:
14
5
2022
Statut:
ppublish
Résumé
Metabolic rewiring fuels rapid cancer cell proliferation by promoting adjustments in energetic resources, and increasing glucose uptake and its conversion into lactate, even in the presence of oxygen. Furthermore, solid tumors often contain hypoxic areas and can rapidly adapt to low oxygen conditions by activating hypoxia inducible factor (HIF)‑1α and several downstream pathways, thus sustaining cell survival and metabolic reprogramming. Since TNF receptor‑associated protein 1 (TRAP1) is a HSP90 molecular chaperone upregulated in several human malignancies and is involved in cancer cell adaptation to unfavorable environments and metabolic reprogramming, in the present study, its role was investigated in the adaptive response to hypoxia in human colorectal cancer (CRC) cells and organoids. In the present study, glucose uptake, lactate production and the expression of key metabolic genes were evaluated in TRAP1‑silenced CRC cell models under conditions of hypoxia/normoxia. Whole genome gene expression profiling was performed in TRAP1‑silenced HCT116 cells exposed to hypoxia to establish the role of TRAP1 in adaptive responses to oxygen deprivation. The results revealed that TRAP1 was involved in regulating hypoxia‑induced HIF‑1α stabilization and glycolytic metabolism and that glucose transporter 1 expression, glucose uptake and lactate production were partially impaired in TRAP1‑silenced CRC cells under hypoxic conditions. At the transcriptional level, the gene expression reprogramming of cancer cells driven by HIF‑1α was partially inhibited in TRAP1‑silenced CRC cells and organoids exposed to hypoxia. Moreover, Gene Set Enrichment Analysis of TRAP1‑silenced HCT116 cells exposed to hypoxia demonstrated that TRAP1 was involved in the regulation of ribosome biogenesis and this occurred with the inhibition of the mTOR pathway. Therefore, as demonstrated herein, TRAP1 is a key factor in maintaining HIF‑1α‑induced genetic/metabolic program under hypoxic conditions and may represent a promising target for novel metabolic therapies.
Identifiants
pubmed: 35543151
doi: 10.3892/ijo.2022.5369
pii: 79
pmc: PMC9097768
doi:
pii:
Substances chimiques
HSP90 Heat-Shock Proteins
0
Hypoxia-Inducible Factor 1, alpha Subunit
0
Lactates
0
TNF Receptor-Associated Factor 1
0
TRAP1 protein, human
0
Glucose
IY9XDZ35W2
Oxygen
S88TT14065
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
J Cell Physiol. 2014 Nov;229(11):1584-94
pubmed: 24604615
Cancer Res. 2010 Aug 15;70(16):6577-86
pubmed: 20647321
Cancer Res. 2017 Apr 1;77(7):1564-1574
pubmed: 28202516
Int J Mol Sci. 2018 Mar 16;19(3):
pubmed: 29547541
Front Oncol. 2017 Mar 29;7:58
pubmed: 28405578
Cancers (Basel). 2021 Jan 03;13(1):
pubmed: 33401572
Semin Cell Dev Biol. 2020 Feb;98:98-104
pubmed: 31128292
Nucleic Acids Res. 2019 Apr 8;47(6):2996-3012
pubmed: 30773582
Genes (Basel). 2018 Apr 05;9(4):
pubmed: 29621137
IUBMB Life. 2011 Feb;63(2):79-85
pubmed: 21360636
Oncotarget. 2015 Mar 30;6(9):7136-50
pubmed: 25762619
Sci Rep. 2017 Jun 9;7(1):3169
pubmed: 28600509
PLoS One. 2013;8(1):e53070
pubmed: 23326384
Nucleic Acids Res. 2015 Aug 18;43(14):7083-95
pubmed: 26117542
Mol Cancer. 2019 Mar 30;18(1):49
pubmed: 30925920
Int J Mol Sci. 2019 Jan 09;20(2):
pubmed: 30634433
Open Life Sci. 2018 Dec 31;13:569-581
pubmed: 33817128
PLoS One. 2020 Jun 12;15(6):e0234932
pubmed: 32530946
Am J Respir Cell Mol Biol. 2018 Feb;58(2):216-231
pubmed: 28915065
Nat Rev Cancer. 2018 Jan;18(1):51-63
pubmed: 29192214
Elife. 2017 Jun 26;6:
pubmed: 28649947
Cell. 2017 Feb 9;168(4):657-669
pubmed: 28187287
Cell Chem Biol. 2017 Sep 21;24(9):1161-1180
pubmed: 28938091
J Biol Chem. 2017 Oct 13;292(41):16825-16832
pubmed: 28842498
Trends Biochem Sci. 2016 Mar;41(3):211-218
pubmed: 26778478
Front Oncol. 2021 Mar 11;11:652266
pubmed: 33777815
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Proc Natl Acad Sci U S A. 2013 Apr 23;110(17):E1604-12
pubmed: 23564345
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Int J Mol Sci. 2021 Mar 05;22(5):
pubmed: 33807717
J Am Chem Soc. 2013 Jul 17;135(28):10418-25
pubmed: 23796364
Wiley Interdiscip Rev RNA. 2015 Jan-Feb;6(1):129-39
pubmed: 25176256
Nat Rev Drug Discov. 2013 Nov;12(11):829-46
pubmed: 24113830
Cells. 2019 Feb 01;8(2):
pubmed: 30717305
Int J Oncol. 2014 Sep;45(3):969-77
pubmed: 24990602
Biochim Biophys Acta. 2015 Jul;1849(7):812-20
pubmed: 25735853
Biomolecules. 2020 Jan 14;10(1):
pubmed: 31947673
Cell. 2015 May 7;161(4):933-45
pubmed: 25957691
Science. 2017 Jan 13;355(6321):
pubmed: 27980088
J Mol Cell Cardiol. 2016 Jun;95:31-41
pubmed: 26773603
Int J Mol Sci. 2021 Sep 09;22(18):
pubmed: 34575924
J Genet Genomics. 2016 Jul 20;43(7):467-9
pubmed: 27474224
Semin Cell Dev Biol. 2014 Dec;36:113-20
pubmed: 25148809
Anticancer Agents Med Chem. 2017;17(2):164-170
pubmed: 27804847
Front Genet. 2021 Feb 24;12:577623
pubmed: 33719329
Mol Cancer. 2019 Nov 11;18(1):157
pubmed: 31711497
Asia Pac J Clin Nutr. 2014;23(1):174-80
pubmed: 24561986
Cell Syst. 2015 Dec 23;1(6):417-425
pubmed: 26771021
Nucleic Acids Res. 2015 Mar 31;43(6):3219-36
pubmed: 25753659
Cancer Lett. 2009 Jun 28;279(1):39-46
pubmed: 19217207
Cancer Lett. 2020 Oct 10;490:124-142
pubmed: 32569616
Molecules. 2020 Oct 20;25(20):
pubmed: 33092283
J Lipid Atheroscler. 2020 Jan;9(1):8-22
pubmed: 32821719
Lancet. 2014 Apr 26;383(9927):1490-1502
pubmed: 24225001
Mol Oncol. 2020 Dec;14(12):3030-3047
pubmed: 33025742
Nat Rev Dis Primers. 2015 Nov 05;1:15065
pubmed: 27189416
Cell. 2018 Jan 11;172(1-2):373-386.e10
pubmed: 29224780
Cell Stem Cell. 2018 Dec 6;23(6):882-897.e11
pubmed: 30344100
Cell Death Differ. 2012 Apr;19(4):592-604
pubmed: 21979464
Cancer Res. 2016 Jul 15;76(14):4259-4269
pubmed: 27261507
Int J Oncol. 2014 Feb;44(2):573-82
pubmed: 24297638
J Physiol. 2021 Jan;599(1):23-37
pubmed: 33006160
Cell Metab. 2013 Jun 4;17(6):988-999
pubmed: 23747254
Cell. 2016 Jul 14;166(2):380-393
pubmed: 27419870
Cells. 2019 Jun 03;8(6):
pubmed: 31163702
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
J Biol Chem. 2020 Jun 5;295(23):8096-8105
pubmed: 32312749
Cancers (Basel). 2018 Jan 03;10(1):
pubmed: 29301334
Chem Sci. 2017 Jun 1;8(6):4188-4202
pubmed: 28878873
J Clin Invest. 2013 Sep;123(9):3664-71
pubmed: 23999440
Cell Cycle. 2015;14(4):473-80
pubmed: 25590164
Biomed Pharmacother. 2021 Sep;141:111798
pubmed: 34120068
Mol Oncol. 2014 Dec;8(8):1482-94
pubmed: 24962791
Cell Death Dis. 2013 Oct 10;4:e851
pubmed: 24113185
EMBO J. 2018 Apr 3;37(7):
pubmed: 29459436
Int J Oncol. 2021 Oct;59(4):
pubmed: 34523696
Trends Pharmacol Sci. 2017 Aug;38(8):669-686
pubmed: 28602395
Mol Cancer Res. 2015 Mar;13(3):556-64
pubmed: 25349289
Front Oncol. 2020 Jul 16;10:1177
pubmed: 32766157
Oncotarget. 2017 Mar 28;8(13):21229-21240
pubmed: 28177905
Cancer Cell. 2017 Nov 13;32(5):624-638.e5
pubmed: 29056426
Nucleic Acids Res. 2014 Sep;42(15):10161-72
pubmed: 25064857
Transl Cancer Res. 2020 Apr;9(4):2824-2837
pubmed: 35117639